Cancer de la prostate à haut risque de récidive: carcinome intracanalaire et microspectroscopie Raman

 

Dominique Trudel

Centre hospitalier de l'Université de Montréal [CHUM]

 

Domaine : cancer

Programme Chercheurs-boursiers cliniciens - Junior 2

Concours 2019-2020

Prostate cancer is the most common cancer in Canadian men. Once diagnosed, one's treatment is planned according to the risk of recurrence, the most aggressive tumours receiving the most aggressive treatments. However, current assessments of the recurrence risk are far from being perfect. It is thus of tremendous importance to be able to identify men with will actually recur to treat them accordingly, while avoiding treatments for men with indolent disease.

In the last four years, my team have been working on intraductal carcinoma of the prostate, an aggressive variant of prostate cancer, and on Raman spectroscopy, a method allowing the detection of prostate cancer. We will pursue our work by better characterizing intraductal carcinoma of the prostate, including by creating an in vitro model of the disease, to allow us to identify the driver alterations of the disease as well as potential therapeutic targets. We will also use Raman spectroscopy, a laser-based method allowing to determine tissular contents, to predict recurrence in men with prostate cancer. Throughout our projects, we will use Raman spectroscopy as surrogate of complex prediction methods or in combination with these.

Furthermore, anatomic pathology is a niche expertise central to mainy biomedical research projects, I will expand my collaborative network by hiring a research pathologist who will increase the efficiency of my work.